Toll-like receptor stimulation in cancer: A pro- and anti-tumor double-edged sword

Immunobiology

Volumn 222, Issue 1, 2017, Pages 89-100

  Dajon, Marion ^a,b,c   Iribarren, Kristina ^a,b,c   Cremer, Isabelle ^a,b,c  

^a INSERM   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Anti tumoral effect; Immune cells; Pro tumoral effect; TLR; TLR signaling; Tumor cells

Indexed keywords

CASPASE 3; CASPASE 8; CASPASE 9; CYCLIN B1; DEFOSLIMOD; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; HIGH MOBILITY GROUP B1 PROTEIN; INTERLEUKIN 6; INTERLEUKIN 8; MYC PROTEIN; MYELOID DIFFERENTIATION FACTOR 88; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PICIBANIL; PROTEIN P16; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 11; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; VASCULOTROPIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER GROWTH; CANCER PROGNOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COLORECTAL CANCER; GLIOBLASTOMA; HUMAN; IMMUNOCOMPETENT CELL; LIGAND BINDING; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; NON SMALL CELL LUNG CANCER; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; REVIEW; TH1 CELL; TH2 CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; AGONISTS; ANIMAL; GENE EXPRESSION REGULATION; GENETICS; IMMUNITY; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; NEOPLASM; PATHOLOGY; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNITY; IMMUNOMODULATION; NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTORS; TUMOR MICROENVIRONMENT;

EID: 84977579665     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2016.06.009     Document Type: Review

References (151)

1. Adams, S., Toll-like receptor agonists in cancer therapy. Immunotherapy 1 (2009), 949–964.
2. Ahmed, A., Wang, J.H., Redmond, H.P., Silencing of TLR4 increases tumor progression and lung metastasis in a murine model of breast cancer. Ann. Surg. Oncol. 20:Suppl. 3 (2013), S389–S396.
3. Akira, S., Uematsu, S., Takeuchi, O., Pathogen recognition and innate immunity. Cell 124 (2006), 783–801.
4. Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M.C., Ullrich, E., Saulnier, P., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat. Med. 13 (2007), 1050–1059.
5. Aspord, C., Tramcourt, L., Leloup, C., Molens, J.-P., Leccia, M.-T., Charles, J., Plumas, J., Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization. J. Invest. Dermatol. 134 (2014), 2551–2561.
6. Balkwill, F., Coussens, L.M., Cancer: an inflammatory link. Nature 431 (2004), 405–406.
7. Balkwill, F., Mantovani, A., Inflammation and cancer: back to Virchow?. Lancet Lond. Engl. 357 (2001), 539–545.
8. Basith, S., Manavalan, B., Lee, G., Kim, S.G., Choi, S., Toll-like receptor modulators: a patent review (2006–2010). Expert Opin. Ther. Pat. 21 (2011), 927–944.
9. Basith, S., Manavalan, B., Yoo, T.H., Kim, S.G., Choi, S., Roles of Toll-like receptors in cancer: a double-edged sword for defense and offense. Arch. Pharm. Res. 35 (2012), 1297–1316.
10. Bauer, A.K., Dixon, D., DeGraff, L.M., Cho, H.-Y., Walker, C.R., Malkinson, A.M., Kleeberger, S.R., Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J. Natl. Cancer Inst. 97 (2005), 1778–1781.
11. Beg, A.A., Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 23 (2002), 509–512.
12. Belmont, L., Rabbe, N., Antoine, M., Cathelin, D., Guignabert, C., Kurie, J., Cadranel, J., Wislez, M., Expression of TLR9 in tumor-infiltrating mononuclear cells enhances angiogenesis and is associated with a worse survival in lung cancer. Int. J. Cancer J. Int. Cancer 134 (2014), 765–777.
13. Berger, R., Fiegl, H., Goebel, G., Obexer, P., Ausserlechner, M., Doppler, W., Hauser-Kronberger, C., Reitsamer, R., Egle, D., Reimer, D., et al. Toll-like receptor 9 expression in breast and ovarian cancer is associated with poorly differentiated tumors. Cancer Sci. 101 (2010), 1059–1066.
14. Bianchi, M.E., DAMPs, PAMPs and alarmins: all we need to know about danger. J. Leukoc. Biol. 81 (2007), 1–5.
15. Brignole, C., Marimpietri, D., Di Paolo, D., Perri, P., Morandi, F., Pastorino, F., Zorzoli, A., Pagnan, G., Loi, M., Caffa, I., et al. Therapeutic targeting of TLR9 inhibits cell growth and induces apoptosis in neuroblastoma. Cancer Res. 70 (2010), 9816–9826.
16. Burdelya, L.G., Gleiberman, A.S., Toshkov, I., Aygun-Sunar, S., Bapardekar, M., Manderscheid-Kern, P., Bellnier, D., Krivokrysenko, V.I., Feinstein, E., Gudkov, A.V., Toll-like receptor 5 agonist protects mice from dermatitis and oral mucositis caused by local radiation: implications for head-and-neck cancer radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 83 (2012), 228–234.
17. Cai, Z., Sanchez, A., Shi, Z., Zhang, T., Liu, M., Zhang, D., Activation of Toll-like receptor 5 on breast cancer cells by flagellin suppresses cell proliferation and tumor growth. Cancer Res. 71 (2011), 2466–2475.
18. Cammarota, R., Bertolini, V., Pennesi, G., Bucci, E.O., Gottardi, O., Garlanda, C., Laghi, L., Barberis, M.C., Sessa, F., Noonan, D.M., et al. The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. J. Transl. Med., 8, 2010, 112.
19. Castaño-Rodríguez, N., Kaakoush, N.O., Mitchell, H.M., Pattern-recognition receptors and gastric cancer. Front. Immunol., 5, 2014, 336.
20. Chatterjee, S., Crozet, L., Damotte, D., Iribarren, K., Schramm, C., Alifano, M., Lupo, A., Cherfils-Vicini, J., Goc, J., Katsahian, S., et al. TLR7 promotes tumor progression, chemotherapy resistance, and poor clinical outcomes in non-small cell lung cancer. Cancer Res. 74 (2014), 5008–5018.
21. Chen, R., Alvero, A.B., Silasi, D.-A., Mor, G., Inflammation, cancer and chemoresistance: taking advantage of the Toll-like receptor signaling pathway. Am. J. Reprod. Immunol. N. Y. 198:57 (2007), 93–107.
22. Chen, X., Zhao, F., Zhang, H., Zhu, Y., Wu, K., Tan, G., Significance of TLR4/MyD88 expression in breast cancer. Int. J. Clin. Exp. Pathol. 8 (2015), 7034–7039.
23. Cherfils-Vicini, J., Platonova, S., Gillard, M., Laurans, L., Validire, P., Caliandro, R., Magdeleinat, P., Mami-Chouaib, F., Dieu-Nosjean, M.-C., Fridman, W.-H., et al. Triggering of TLR7 and TLR8 expressed by human lung cancer cells induces cell survival and chemoresistance. J. Clin. Invest. 120 (2010), 1285–1297.
24. Chew, V., Tow, C., Huang, C., Bard-Chapeau, E., Copeland, N.G., Jenkins, N.A., Weber, A., Lim, K.H., Toh, H.C., Heikenwalder, M., et al. Toll-like receptor 3 expressing tumor parenchyma and infiltrating natural killer cells in hepatocellular carcinoma patients. J. Natl. Cancer Inst. 104 (2012), 1796–1807.
25. Chicoine, M.R., Zahner, M., Won, E.K., Kalra, R.R., Kitamura, T., Perry, A., Higashikubo, R., The in vivo antitumoral effects of lipopolysaccharide against glioblastoma multiforme are mediated in part by Toll-like receptor 4. Neurosurgery 60 (2007), 372–380 (discussion 381).
26. Chin, A.I., Miyahira, A.K., Covarrubias, A., Teague, J., Guo, B., Dempsey, P.W., Cheng, G., Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance. Cancer Res. 70 (2010), 2595–2603.
27. Coussens, L.M., Werb, Z., Inflammation and cancer. Nature 420 (2002), 860–867.
28. D'Agostini, C., Pica, F., Febbraro, G., Grelli, S., Chiavaroli, C., Garaci, E., Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5 (2005), 1205–1212.
29. Dajon, M., Iribarren, K., Cremer, I., Dual roles of TLR7 in the lung cancer microenvironment. Oncoimmunology, 4, 2015, e991615.
30. Dapito, D.H., Mencin, A., Gwak, G.-Y., Pradere, J.-P., Jang, M.-K., Mederacke, I., Caviglia, J.M., Khiabanian, H., Adeyemi, A., Bataller, R., et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4. Cancer Cell 21 (2012), 504–516.
31. De Cesare, M., Calcaterra, C., Pratesi, G., Gatti, L., Zunino, F., Mènard, S., Balsari, A., Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin. Cancer Res. 14 (2008), 5512–5518.
32. Dranoff, G., Coordinated tumor immunity. J. Clin. Invest. 111 (2003), 1116–1118.
33. Droemann, D., Albrecht, D., Gerdes, J., Ulmer, A.J., Branscheid, D., Vollmer, E., Dalhoff, K., Zabel, P., Goldmann, T., Human lung cancer cells express functionally active Toll-like receptor 9. Respir. Res., 6, 2005, 1.
34. Dunn, G.P., Old, L.J., Schreiber, R.D., The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004), 329–360.
35. El Andaloussi, A., Sonabend, A.M., Han, Y., Lesniak, M.S., Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors. Glia 54 (2006), 526–535.
36. Farnebo, L., Shahangian, A., Lee, Y., Shin, J.H., Scheeren, F.A., Sunwoo, J.B., Targeting Toll-like receptor 2 inhibits growth of head and neck squamous cell carcinoma. Oncotarget 6 (2015), 9897–9907.
37. Fernandez-Garcia, B., Eiró, N., González-Reyes, S., González, L., Aguirre, A., González, L.O., Del Casar, J.M., García-Muñiz, J.L., Vizoso, F.J., Clinical significance of Toll-like receptor 3, 4, and 9 in gastric cancer. J. Immunother. Hagerstown Md. 1997:37 (2014), 77–83.
38. Figueiredo, R.T., Fernandez, P.L., Mourao-Sa, D.S., Porto, B.N., Dutra, F.F., Alves, L.S., Oliveira, M.F., Oliveira, P.L., Graça-Souza, A.V., Bozza, M.T., Characterization of heme as activator of Toll-like receptor 4. J. Biol. Chem. 282 (2007), 20221–20229.
39. Fridman, W.H., Pagès, F., Sautès-Fridman, C., Galon, J., The immune contexture in human tumours: impact on clinical outcome. Nat. Rev. Cancer 12 (2012), 298–306.
40. Fukata, M., Chen, A., Vamadevan, A.S., Cohen, J., Breglio, K., Krishnareddy, S., Hsu, D., Xu, R., Harpaz, N., Dannenberg, A.J., et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology 133 (2007), 1869–1881.
41. Gambara, G., Desideri, M., Stoppacciaro, A., Padula, F., De Cesaris, P., Starace, D., Tubaro, A., Del Bufalo, D., Filippini, A., Ziparo, E., et al. TLR3 engagement induces IRF-3-dependent apoptosis in androgen-sensitive prostate cancer cells and inhibits tumour growth in vivo. J. Cell. Mol. Med. 19 (2015), 327–339.
42. Geng, D., Kaczanowska, S., Tsai, A., Younger, K., Ochoa, A., Rapoport, A.P., Ostrand-Rosenberg, S., Davila, E., TLR5 ligand-secreting t cells reshape the tumor microenvironment and enhance antitumor activity. Cancer Res. 75 (2015), 1959–1971.
43. Gershan, J.A., Barr, K.M., Weber, J.J., Jing, W., Johnson, B.D., Immune modulating effects of cyclophosphamide and treatment with tumor lysate/CpG synergize to eliminate murine neuroblastoma. J. Immunother. Cancer, 3, 2015, 24.
44. González-Reyes, S., Fernández, J.M., González, L.O., Aguirre, A., Suárez, A., González, J.M., Escaff, S., Vizoso, F.J., Study of TLR3, TLR4, and TLR9 in prostate carcinomas and their association with biochemical recurrence. Cancer Immunol. Immunother. CII 60 (2011), 217–226.
45. Greten, F.R., Eckmann, L., Greten, T.F., Park, J.M., Li, Z.-W., Egan, L.J., Kagnoff, M.F., Karin, M., IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 118 (2004), 285–296.
46. Grimm, M., Kim, M., Rosenwald, A., Heemann, U., Germer, C.-T., Waaga-Gasser, A.M., Gasser, M., Toll-like receptor (TLR) 7 and TLR8 expression on CD133+ cells in colorectal cancer points to a specific role for inflammation-induced TLRs in tumourigenesis and tumour progression. Eur. J. Cancer Oxf. Engl. 1990:46 (2010), 2849–2857.
47. Grimmig, T., Matthes, N., Hoeland, K., Tripathi, S., Chandraker, A., Grimm, M., Moench, R., Moll, E.-M., Friess, H., Tsaur, I., et al. TLR7 and TLR8 expression increases tumor cell proliferation and promotes chemoresistance in human pancreatic cancer. Int. J. Oncol. 47 (2015), 857–866.
48. Gu, J., Sun, R., Shen, S., Yu, Z., The influence of TLR4 agonist lipopolysaccharides on hepatocellular carcinoma cells and the feasibility of its application in treating liver cancer. OncoTargets Ther. 8 (2015), 2215–2225.
49. Hanahan, D., Weinberg, R.A., The hallmarks of cancer. Cell 100 (2000), 57–70.
50. Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
51. Hasan, U., Chaffois, C., Gaillard, C., Saulnier, V., Merck, E., Tancredi, S., Guiet, C., Brière, F., Vlach, J., Lebecque, S., et al. Human TLR10 is a functional receptor, expressed by B cells and plasmacytoid dendritic cells, which activates gene transcription through MyD88. J. Immunol. Baltim. Md 1950:174 (2005), 2942–2950.
52. Hausmann, M., Kiessling, S., Mestermann, S., Webb, G., Spöttl, T., Andus, T., Schölmerich, J., Herfarth, H., Ray, K., Falk, W., et al. Toll-like receptors 2 and 4 are up-regulated during intestinal inflammation. Gastroenterology 122 (2002), 1987–2000.
53. He, W., Liu, Q., Wang, L., Chen, W., Li, N., Cao, X., TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol. Immunol. 44 (2007), 2850–2859.
54. Hertz, C.J., Wu, Q., Porter, E.M., Zhang, Y.J., Weismüller, K.-H., Godowski, P.J., Ganz, T., Randell, S.H., Modlin, R.L., Activation of Toll-like receptor 2 on human tracheobronchial epithelial cells induces the antimicrobial peptide human beta defensin-2. J. Immunol. Baltim. Md 1950:171 (2003), 6820–6826.
55. Ho, V., Lim, T.S., Lee, J., Steinberg, J., Szmyd, R., Tham, M., Yaligar, J., Kaldis, P., Abastado, J.-P., Chew, V., TLR3 agonist and Sorafenib combinatorial therapy promotes immune activation and controls hepatocellular carcinoma progression. Oncotarget, 2015.
56. Hopkins, P.A., Sriskandan, S., Mammalian Toll-like receptors: to immunity and beyond. Clin. Exp. Immunol. 140 (2005), 395–407.
57. Hornef, M.W., Normark, B.H., Vandewalle, A., Normark, S., Intracellular recognition of lipopolysaccharide by Toll-like receptor 4 in intestinal epithelial cells. J. Exp. Med. 198 (2003), 1225–1235.
58. Hornung, V., Rothenfusser, S., Britsch, S., Krug, A., Jahrsdörfer, B., Giese, T., Endres, S., Hartmann, G., Quantitative expression of Toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J. Immunol. Baltim. Md 1950:168 (2002), 4531–4537.
59. Hsiao, C.-C., Chen, P.-H., Cheng, C.-I., Tsai, M.-S., Chang, C.-Y., Lu, S.-C., Hsieh, M.-C., Lin, Y.-C., Lee, P.-H., Kao, Y.-H., Toll-like receptor-4 is a target for suppression of proliferation and chemoresistance in HepG2 hepatoblastoma cells. Cancer Lett. 368 (2015), 144–152.
60. Huang, B., Zhao, J., Li, H., He, K.-L., Chen, Y., Chen, S.-H., Mayer, L., Unkeless, J.C., Xiong, H., Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res. 65 (2005), 5009–5014.
61. Huang, B., Zhao, J., Shen, S., Li, H., He, K.-L., Shen, G.-X., Mayer, L., Unkeless, J., Li, D., Yuan, Y., et al. Listeria monocytogenes promotes tumor growth via tumor cell Toll-like receptor 2 signaling. Cancer Res. 67 (2007), 4346–4352.
62. Huen, A.O., Rook, A.H., Toll receptor agonist therapy of skin cancer and cutaneous T-cell lymphoma. Curr. Opin. Oncol. 26 (2014), 237–244.
63. Husseinzadeh, N., Davenport, S.M., Role of Toll-like receptors in cervical, endometrial and ovarian cancers: a review. Gynecol. Oncol. 135 (2014), 359–363.
64. Jahrsdörfer, B., Wooldridge, J.E., Blackwell, S.E., Taylor, C.M., Griffith, T.S., Link, B.K., Weiner, G.J., Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J. Leukoc. Biol. 77 (2005), 378–387.
65. Jain, S., Suklabaidya, S., Das, B., Raghav, S.K., Batra, S.K., Senapati, S., TLR4 activation by lipopolysaccharide confers survival advantage to growth factor deprived prostate cancer cells. The Prostate 75 (2015), 1020–1033.
66. Janeway, C.A., Medzhitov, R., Innate immune recognition. Annu. Rev. Immunol. 20 (2002), 197–216.
67. Jego, G., Bataille, R., Geffroy-Luseau, A., Descamps, G., Pellat-Deceunynck, C., Pathogen-associated molecular patterns are growth and survival factors for human myeloma cells through Toll-like receptors. Leukemia 20 (2006), 1130–1137.
68. Jiang, Q., Wei, H., Tian, Z., Poly I:C enhances cycloheximide-induced apoptosis of tumor cells through TLR3 pathway. BMC Cancer, 8, 2008, 12.
69. Karikó, K., Ni, H., Capodici, J., Lamphier, M., Weissman, D., mRNA is an endogenous ligand for Toll-like receptor 3. J. Biol. Chem. 279 (2004), 12542–12550.
70. Karin, M., Nuclear factor-kappaB in cancer development and progression. Nature 441 (2006), 431–436.
71. Kawai, T., Akira, S., The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11 (2010), 373–384.
72. Kelly, M.G., Alvero, A.B., Chen, R., Silasi, D.-A., Abrahams, V.M., Chan, S., Visintin, I., Rutherford, T., Mor, G., TLR-4 signaling promotes tumor growth and paclitaxel chemoresistance in ovarian cancer. Cancer Res. 66 (2006), 3859–3868.
73. Kundu, S.D., Lee, C., Billips, B.K., Habermacher, G.M., Zhang, Q., Liu, V., Wong, L.Y., Klumpp, D.J., Thumbikat, P., The Toll-like receptor pathway: a novel mechanism of infection-induced carcinogenesis of prostate epithelial cells. The Prostate 68 (2008), 223–229.
74. Le Mercier, I., Poujol, D., Sanlaville, A., Sisirak, V., Gobert, M., Durand, I., Dubois, B., Treilleux, I., Marvel, J., Vlach, J., et al. Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. Cancer Res. 73 (2013), 4629–4640.
75. Leigh, N.D., Bian, G., Ding, X., Liu, H., Aygun-Sunar, S., Burdelya, L.G., Gudkov, A.V., Cao, X., A flagellin-derived Toll-like receptor 5 agonist stimulates cytotoxic lymphocyte-mediated tumor immunity. PLoS One, 9, 2014, e85587.
76. Lemaitre, B., Nicolas, E., Michaut, L., Reichhart, J.M., Hoffmann, J.A., The dorsoventral regulatory gene cassette spätzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell 86 (1996), 973–983.
77. Li, S., Sun, R., Chen, Y., Wei, H., Tian, Z., TLR2 limits development of hepatocellular carcinoma by reducing IL18-mediated immunosuppression. Cancer Res. 75 (2015), 986–995.
78. Li, Y., Shi, Y., McCaw, L., Li, Y.-J., Zhu, F., Gorczynski, R., Duncan, G.S., Yang, B., Ben-David, Y., Spaner, D.E., Microenvironmental interleukin-6 suppresses Toll-like receptor signaling in human leukemia cells through miR-17/19A. Blood 126 (2015), 766–778.
79. Lin, H., Yan, J., Wang, Z., Hua, F., Yu, J., Sun, W., Li, K., Liu, H., Yang, H., Lv, Q., et al. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice. Hepatol. Baltim. Md 57 (2013), 171–182.
80. Liu, Y., Yan, W., Tohme, S., Chen, M., Fu, Y., Tian, D., Lotze, M., Tang, D., Tsung, A., Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through Toll-like receptor 9. J. Hepatol. 63 (2015), 114–121.
81. Lohs-Schardin, M., Cremer, C., Nüsslein-Volhard, C., A fate map for the larval epidermis of Drosophila melanogaster: localized cuticle defects following irradiation of the blastoderm with an ultraviolet laser microbeam. Dev. Biol. 73 (1979), 239–255.
82. Lowe, E.L., Crother, T.R., Rabizadeh, S., Hu, B., Wang, H., Chen, S., Shimada, K., Wong, M.H., Michelsen, K.S., Arditi, M., Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One, 5, 2010, e13027.
83. Luo, Y., Jiang, Q.-W., Wu, J.-Y., Qiu, J.-G., Zhang, W.-J., Mei, X.-L., Shi, Z., Di, J.-M., Regulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer. Oncotarget 6 (2015), 22564–22574.
84. Ma, F.-J., Liu, Z.-B., Hu, X., Ling, H., Li, S., Wu, J., Shao, Z.-M., Prognostic value of myeloid differentiation primary response 88 and Toll-like receptor 4 in breast cancer patients. PLoS One, 9, 2014, e111639.
85. Mai, C.W., Kang, Y.B., Pichika, M.R., Should a Toll-like receptor 4 (TLR-4) agonist or antagonist be designed to treat cancer? TLR-4: its expression and effects in the ten most common cancers. OncoTargets Ther. 6 (2013), 1573–1587.
86. Martin, M.U., Wesche, H., Summary and comparison of the signaling mechanisms of the toll/interleukin-1 receptor family. Biochim. Biophys. Acta 1592 (2002), 265–280.
87. Maruyama, A., Shime, H., Takeda, Y., Azuma, M., Matsumoto, M., Seya, T., Pam2 lipopeptides systemically increase myeloid-derived suppressor cells through TLR2 signaling. Biochem. Biophys. Res. Commun. 457 (2015), 445–450.
88. Matijevic, T., Marjanovic, M., Pavelic, J., Functionally active Toll-like receptor 3 on human primary and metastatic cancer cells. Scand. J. Immunol. 70 (2009), 18–24.
89. Medzhitov, R., Preston-Hurlburt, P., Janeway, C.A., A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388 (1997), 394–397.
90. Medzhitov, R., Preston-Hurlburt, P., Kopp, E., Stadlen, A., Chen, C., Ghosh, S., Janeway, C.A., MyD88 is an adaptor protein in the hToll/IL-1 receptor family signaling pathways. Mol. Cell 2 (1998), 253–258.
91. Molteni, M., Marabella, D., Orlandi, C., Rossetti, C., Melanoma cell lines are responsive in vitro to lipopolysaccharide and express TLR-4. Cancer Lett. 235 (2006), 75–83.
92. Moreira, D., Zhang, Q., Hossain, D.M.S., Nechaev, S., Li, H., Kowolik, C.M., D'Apuzzo, M., Forman, S., Jones, J., Pal, S.K., et al. TLR9 signaling through NF-(B/RELA and STAT3 promotes tumor-propagating potential of prostate cancer cells. Oncotarget 6 (2015), 17302–17313.
93. Muccioli, M., Benencia, F., Toll-like receptors in ovarian cancer as targets for immunotherapies. Front. Immunol., 5, 2014, 341.
94. Muir, A., Soong, G., Sokol, S., Reddy, B., Gomez, M.I., Van Heeckeren, A., Prince, A., Toll-like receptors in normal and cystic fibrosis airway epithelial cells. Am. J. Respir. Cell Mol. Biol. 30 (2004), 777–783.
95. Nagase, H., Okugawa, S., Ota, Y., Yamaguchi, M., Tomizawa, H., Matsushima, K., Ohta, K., Yamamoto, K., Hirai, K., Expression and function of Toll-like receptors in eosinophils: activation by Toll-like receptor 7 ligand. J. Immunol. Baltim. Md 195:171 (2003), 3977–3982.
96. Naseemuddin, M., Iqbal, A., Nasti, T.H., Ghandhi, J.L., Kapadia, A.D., Yusuf, N., Cell mediated immune responses through TLR4 prevents DMBA-induced mammary carcinogenesis in mice. Int. J. Cancer J. Int. Cancer 130 (2012), 765–774.
97. Newton, K., Dixit, V.M., Signaling in innate immunity and inflammation. Cold Spring Harb. Perspect. Biol., 4, 2012.
98. Nomi, N., Kodama, S., Suzuki, M., Toll-like receptor 3 signaling induces apoptosis in human head and neck cancer via survivin associated pathway. Oncol. Rep. 24 (2010), 225–231.
99. Ochi, A., Graffeo, C.S., Zambirinis, C.P., Rehman, A., Hackman, M., Fallon, N., Barilla, R.M., Henning, J.R., Jamal, M., Rao, R., et al. Toll-like receptor 7 regulates pancreatic carcinogenesis in mice and humans. J. Clin. Invest. 122 (2012), 4118–4129.
100. Okamoto, M., Oshikawa, T., Tano, T., Ohe, G., Furuichi, S., Nishikawa, H., Ahmed, S.U., Akashi, S., Miyake, K., Takeuchi, O., et al. Involvement of Toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J. Natl. Cancer Inst. 95 (2003), 316–326.
101. Oosting, M., Cheng, S.-C., Bolscher, J.M., Vestering-Stenger, R., Plantinga, T.S., Verschueren, I.C., Arts, P., Garritsen, A., van Eenennaam, H., Sturm, P., et al. Human TLR10 is an anti-inflammatory pattern-recognition receptor. Proc. Natl. Acad. Sci. U. S. A. 111 (2014), E4478–E4484.
102. Pagès, F., Galon, J., Dieu-Nosjean, M.-C., Tartour, E., Sautès-Fridman, C., Fridman, W.-H., Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29 (2010), 1093–1102.
103. Pandey, S., Agrawal, D.K., Immunobiology of Toll-like receptors: emerging trends. Immunol. Cell Biol. 84 (2006), 333–341.
104. Paone, A., Starace, D., Galli, R., Padula, F., De Cesaris, P., Filippini, A., Ziparo, E., Riccioli, A., Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 29 (2008), 1334–1342.
105. Park, J.-H., Yoon, H.-E., Kim, D.-J., Kim, S.-A., Ahn, S.-G., Yoon, J.-H., Toll-like receptor 5 activation promotes migration and invasion of salivary gland adenocarcinoma. J. Oral Pathol. Med. 40 (2011), 187–193.
106. Piccinini, A.M., Midwood, K.S., DAMPening inflammation by modulating TLR signalling. Mediators Inflamm., 2010, 2010.
107. Pikarsky, E., Porat, R.M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., Ben-Neriah, Y., NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431 (2004), 461–466.
108. Pimentel-Nunes, P., Afonso, L., Lopes, P., Roncon-Albuquerque, R., Gonçalves, N., Henrique, R., Moreira-Dias, L., Leite-Moreira, A.F., Dinis-Ribeiro, M., Increased expression of Toll-like receptors (TLR) 2, 4 and 5 in gastric dysplasia. Pathol. Oncol. Res. POR 17 (2011), 677–683.
109. Pradere, J.-P., Dapito, D.H., Schwabe, R.F., The yin and yang of toll-like receptors in cancer. Oncogene 33 (2014), 3485–3495.
110. Rhee, S.H., Im, E., Pothoulakis, C., Toll-like receptor 5 engagement modulates tumor development and growth in a mouse xenograft model of human colon cancer. Gastroenterology 135 (2008), 518–528.
111. Rock, F.L., Hardiman, G., Timans, J.C., Kastelein, R.A., Bazan, J.F., A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 588–593.
112. Ronkainen, H., Hirvikoski, P., Kauppila, S., Vuopala, K.S., Paavonen, T.K., Selander, K.S., Vaarala, M.H., Absent toll-like receptor-9 expression predicts poor prognosis in renal cell carcinoma. J. Exp. Clin. Cancer Res. CR, 30, 2011, 84.
113. Rutkowski, M.R., Stephen, T.L., Svoronos, N., Allegrezza, M.J., Tesone, A.J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J.M., Cadungog, M.G., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27 (2015), 27–40.
114. Salaun, B., Lebecque, S., Matikainen, S., Rimoldi, D., Romero, P., Toll-like receptor 3 expressed by melanoma cells as a target for therapy?. Clin. Cancer Res. 13 (2007), 4565–4574.
115. Sato, T., Shimosato, T., Ueda, A., Ishigatsubo, Y., Klinman, D.M., Intrapulmonary delivery of CpG microparticles eliminates lung tumors. Mol. Cancer Ther. 14 (2015), 2198–2205.
116. Scheeren, F.A., Kuo, A.H., van Weele, L.J., Cai, S., Glykofridis, I., Sikandar, S.S., Zabala, M., Qian, D., Lam, J.S., Johnston, D., et al. A cell-intrinsic role for TLR2-MYD88 in intestinal and breast epithelia and oncogenesis. Nat. Cell Biol. 16 (2014), 1238–1248.
117. Schmausser, B., Andrulis, M., Endrich, S., Müller-Hermelink, H.-K., Eck, M., Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int. J. Med. Microbiol. IJMM 295 (2005), 179–185.
118. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
119. Shi, W., Su, L., Li, Q., Sun, L., Lv, J., Li, J., Cheng, B., Suppression of Toll-like receptor 2 expression inhibits the bioactivity of human hepatocellular carcinoma. Tumour Biol. 35 (2014), 9627–9637.
120. Shime, H., Matsumoto, M., Oshiumi, H., Tanaka, S., Nakane, A., Iwakura, Y., Tahara, H., Inoue, N., Seya, T., Toll-like receptor 3 signaling converts tumor-supporting myeloid cells to tumoricidal effectors. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 2066–2071.
121. Shojaei, H., Oberg, H.-H., Juricke, M., Marischen, L., Kunz, M., Mundhenke, C., Gieseler, F., Kabelitz, D., Wesch, D., Toll-like receptors 3 and 7 agonists enhance tumor cell lysis by human gammadelta T cells. Cancer Res. 69 (2009), 8710–8717.
122. Song, E.-J., Kang, M.-J., Kim, Y.-S., Kim, S.-M., Lee, S.-E., Kim, C.-H., Kim, D.-J., Park, J.-H., Flagellin promotes the proliferation of gastric cancer cells via the Toll-like receptor 5. Int. J. Mol. Med. 28 (2011), 115–119.
123. Spaner, D.E., Shi, Y., White, D., Mena, J., Hammond, C., Tomic, J., He, L., Tomai, M.A., Miller, R.L., Booth, J., et al. Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells. Leukemia 20 (2006), 286–295.
124. Spaner, D.E., Shi, Y., White, D., Shaha, S., He, L., Masellis, A., Wong, K., Gorczynski, R., A phase I/II trial of TLR-7 agonist immunotherapy in chronic lymphocytic leukemia. Leukemia 24 (2010), 222–226.
125. Szczepański, M., Stelmachowska, M., Stryczyński, L., Golusiński, W., Samara, H., Mozer-Lisewska, I., Zeromski, J., Assessment of expression of Toll-like receptors 2, 3 and 4 in laryngeal carcinoma. Eur. Arch. Oto-Rhino-Laryngol. 264 (2007), 525–530.
126. Szczepanski, M.J., Czystowska, M., Szajnik, M., Harasymczuk, M., Boyiadzis, M., Kruk-Zagajewska, A., Szyfter, W., Zeromski, J., Whiteside, T.L., Triggering of Toll-like receptor 4 expressed on human head and neck squamous cell carcinoma promotes tumor development and protects the tumor from immune attack. Cancer Res. 69 (2009), 3105–3113.
127. Takemura, R., Takaki, H., Okada, S., Shime, H., Akazawa, T., Oshiumi, H., Matsumoto, M., Teshima, T., Seya, T., PolyI:C-induced, TLR3/RIP3-dependent necroptosis backs up immune effector-Mediated tumor elimination in vivo. Cancer Immunol. Res. 3 (2015), 902–914.
128. Theodoropoulos, G.E., Saridakis, V., Karantanos, T., Michalopoulos, N.V., Zagouri, F., Kontogianni, P., Lymperi, M., Gazouli, M., Zografos, G.C., Toll-like receptors gene polymorphisms may confer increased susceptibility to breast cancer development. Breast Edinb. Scotl. 21 (2012), 534–538.
129. Trinchieri, G., Cancer and inflammation: an old intuition with rapidly evolving new concepts. Annu. Rev. Immunol. 30 (2012), 677–706.
130. Tye, H., Kennedy, C.L., Najdovska, M., McLeod, L., McCormack, W., Hughes, N., Dev, A., Sievert, W., Ooi, C.H., Ishikawa, T., et al. STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation. Cancer Cell 22 (2012), 466–478.
131. Vacchelli, E., Eggermont, A., Sautès-Fridman, C., Galon, J., Zitvogel, L., Kroemer, G., Galluzzi, L., Trial watch: toll-like receptor agonists for cancer therapy. Oncoimmunology, 2, 2013, e25238.
132. Vollmer, J., Tluk, S., Schmitz, C., Hamm, S., Jurk, M., Forsbach, A., Akira, S., Kelly, K.M., Reeves, W.H., Bauer, S., et al. Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8. J. Exp. Med. 202 (2005), 1575–1585.
133. Wang, C., Cao, S., Yan, Y., Ying, Q., Jiang, T., Xu, K., Wu, A., TLR9 expression in glioma tissues correlated to glioma progression and the prognosis of GBM patients. BMC Cancer, 10, 2010, 415.
134. Wang, J.-P., Zhang, Y., Wei, X., Li, J., Nan, X.-P., Yu, H.-T., Li, Y., Wang, P.-Z., Bai, X.-F., Circulating toll-like receptor (TLR) 2, TLR4, and regulatory T cells in patients with chronic hepatitis C: APMIS acta pathol. Microbiol. Immunol. Scand. 118 (2010), 261–270.
135. Wang, Z., Yan, J., Lin, H., Hua, F., Wang, X., Liu, H., Lv, X., Yu, J., Mi, S., Wang, J., et al. Toll-like receptor 4 activity protects against hepatocellular tumorigenesis and progression by regulating expression of DNA repair protein Ku70 in mice. Hepatol. Baltim. Md 57 (2013), 1869–1881.
136. Xie, W., Wang, Y., Huang, Y., Yang, H., Wang, J., Hu, Z., Toll-like receptor 2 mediates invasion via activating NF-kappaB in MDA-MB-231 breast cancer cells. Biochem. Biophys. Res. Commun. 379 (2009), 1027–1032.
137. Xu, Y.-Y., Chen, L., Zhou, J.-M., Wu, Y.-Y., Zhu, Y.-Y., Inhibitory effect of dsRNA TLR3 agonist in a rat hepatocellular carcinoma model. Mol. Med. Rep. 8 (2013), 1037–1042.
138. Xu, Y.-Y., Chen, L., Wang, G.-L., Zhou, J.-M., Zhang, Y.-X., Wei, Y.-Z., Zhu, Y.-Y., Qin, J., A synthetic dsRNA, as a TLR3 pathwaysynergist, combined with sorafenib suppresses HCC in vitro and in vivo. BMC Cancer, 13, 2013, 527.
139. Yang, H., Zhou, H., Feng, P., Zhou, X., Wen, H., Xie, X., Shen, H., Zhu, X., Reduced expression of Toll-like receptor 4 inhibits human breast cancer cells proliferation and inflammatory cytokines secretion. J. Exp. Clin. Cancer Res. CR, 29, 2010, 92.
140. Yang, H., Wang, B., Wang, T., Xu, L., He, C., Wen, H., Yan, J., Su, H., Zhu, X., Toll-like receptor 4 prompts human breast cancer cells invasiveness via lipopolysaccharide stimulation and is overexpressed in patients with lymph node metastasis. PLoS One, 9, 2014, e109980.
141. Yesudhas, D., Gosu, V., Anwar, M.A., Choi, S., Multiple roles of Toll-like receptor 4 in colorectal cancer. Front. Immunol., 5, 2014, 334.
142. Yoneda, K., Sugimoto, K., Shiraki, K., Tanaka, J., Beppu, T., Fuke, H., Yamamoto, N., Masuya, M., Horie, R., Uchida, K., et al. Dual topology of functional Toll-like receptor 3 expression in human hepatocellular carcinoma: differential signaling mechanisms of TLR3-induced NF-kappaB activation and apoptosis. Int. J. Oncol. 33 (2008), 929–936.
143. Yusuf, N., Nasti, T.H., Long, J.A., Naseemuddin, M., Lucas, A.P., Xu, H., Elmets, C.A., Protective role of Toll-like receptor 4 during the initiation stage of cutaneous chemical carcinogenesis. Cancer Res. 68 (2008), 615–622.
144. Zambirinis, C.P., Levie, E., Nguy, S., Avanzi, A., Barilla, R., Xu, Y., Seifert, L., Daley, D., Greco, S.H., Deutsch, M., et al. TLR9 ligation in pancreatic stellate cells promotes tumorigenesis. J. Exp. Med. 212 (2015), 2077–2094.
145. Zhang, J.-J., Wu, H.-S., Wang, L., Tian, Y., Zhang, J.-H., Wu, H.-L., Expression and significance of TLR4 and HIF-1alpha in pancreatic ductal adenocarcinoma. World J. Gastroenterol. WJG 16 (2010), 2881–2888.
146. Zhang, Y., Luo, F., Cai, Y., Liu, N., Wang, L., Xu, D., Chu, Y., TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J. Immunol. Baltim. Md 1950:186 (2011), 1963–1969.
147. Zhang, Y., Wang, Q., Ma, A., Li, Y., Li, R., Wang, Y., Functional expression of TLR9 in esophageal cancer. Oncol. Rep. 31 (2014), 2298–2304.
148. Zhou, S.-X., Li, F.-S., Qiao, Y.-L., Zhang, X.-Q., Wang, Z.-D., Toll-like receptor 5 agonist inhibition of growth of A549 lung cancer cells in vivo in a Myd88 dependent manner. Asian Pac. J. Cancer Prev. APJCP 13 (2012), 2807–2812.
149. Zhou, H., Chen, J., Hu, J., Luo, Y., Li, F., Xiao, L., Zhong, M., High expression of Toll-like receptor 5 correlates with better prognosis in non-small-cell lung cancer: an anti-tumor effect of TLR5 signaling in non-small cell lung cancer. J. Cancer Res. Clin. Oncol. 140 (2014), 633–643.
150. Zhou, Z., Yu, X., Zhang, J., Tian, Z., Zhang, C., TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 369 (2015), 298–306.
151. Zhu, J., He, S., Du, J., Wang, Z., Li, W., Chen, X., Jiang, W., Zheng, D., Jin, G., Local administration of a novel Toll-like receptor 7 agonist in combination with doxorubicin induces durable tumouricidal effects in a murine model of T cell lymphoma. J. Hematol. Oncol., 8, 2015, 21.